Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 131

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 131
---
 toxicity and side effects which is in pre-clinical studies. The Predecessor undertook to finance the research program. Upon completion of the research plan, the Company will be able to decide whether it wants to license the technology. If so, a licensing agreement will be signed.

LV-400 – A Liposomal Platform for Vaccine Development: This platform is intended for the development of new vaccines, such as those for COVID-19, Zika, and West Nile virus. The Predecessor is obligated to pay royalties at the rate of 3% of net sales. The Predecessor shall pay Yissum the following amounts in connection with the achievement of the following milestones per each Product (each, a “Milestone”): (1) $150 upon first patient enrolled in a Phase I Clinical Trial; (2) $300 upon first patient enrolled in a Phase II Clinical Trial; (3) $450 upon First patient enrolled in a Phase III Clinical Trial and (4) $600 upon first commercial sale in either Europe or the US, the earlier to occur of the two.

<div align='center'>F-25</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands, except share and per share data

NOTE 12 – SELECTED STATEMENTS OF OPERATIONS DATA

| a. | Research                  
 and development expenses: |

|                                |     | Successor 
 Unaudited 
 2024      | For the period commencing July 24, through 
                              September 30, |     | Predecessor 
 audited     
 2024        | For the period commencing January 1, through 
                                     July 23, |     | 2023 | Year ended  December 31, |     | 2022 |     |
|:-------------------------------|:----|:----------|-------------------------------------------:|:----|:------------|---------------------------------------------:|:----|:-----|-------------------------:|:----|:-----|----:|
| Subcontractors and consultants |     |           |                                         50 |     |             |                                          354 |     |      |                      490 |     |      | 324 |
| Share based payment            |     |           |                                        230 |     |             |                                          710 |     |      |                      205 |     |      |   - |
| Payroll and related expenses   |     |           |